ribosomal protein L39Genealiases: L39 · RPL39P42 · RPL39_23_1806 · eL39
Q-omics provides the consensus-scored RPL39 profile across patient tissues and cancer cell-line models. RPL39 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL39 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RPL39 RNA expression shows 18,609 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where RPL39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39 survival associations across molecular data types. RPL39 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39 RNA expression–survival associations across cancer types. High RPL39 expression shows unfavorable associations in KIRP, HNSC, KICH, SARC, ACC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL39 RNA expression.
This table summarizes RPL39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPL39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39 shows higher tumor expression in KIRC, LIHC, HNSC, KIRP, CHOL and STAD. The KIRC box plot shows higher RPL39 RNA expression in tumor versus normal tissue (log2 FC = +1.030, t-test p < 0.001).
This table shows molecular features associated with RPL39 in patient tissues and cancer cell lines. In patient samples, RPL39 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
